Grafton, WI (March 24, 2014) — Cedarburg Pharmaceuticals, Inc. today announced that it has signed a definitive agreement to be acquired by Albany Molecular Research Inc. (NASDAQ: AMRI), a global contract research and manufacturing organization. The transaction is expected to close in early April 2014.
Theron E. Odlaug, Ph.D., Cedarburg’s executive chairman, commented, “The Company’s board of directors would like to thank Tony Laughrey, CEO, and his management team for their efforts in bringing the company to this point. Mr. Laughrey added “It has been my pleasure to work with such a dedicated group of employees over the last seven years and I am sure the combination with AMRI will be welcomed by our customers.”
Wells Fargo Securities, LLC acted as exclusive financial advisor to Cedarburg Pharmaceuticals, Inc. and Polsinelli PC (Kansas City) provided legal support.
About Cedarburg Pharmaceuticals, Inc.
Cedarburg Hauser Pharmaceuticals is an experienced contract development and manufacturing company for active pharmaceutical ingredients (API) and pharmaceutical intermediates that combines the benefits of working with a contract research organization (CRO) and a contract manufacturing organization.
About Albany Molecular Research, Inc.
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 22 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).